[
  {
    "ts": null,
    "headline": "Labcorp’s Q3 Earnings Call: Our Top 5 Analyst Questions",
    "summary": "Labcorp’s third quarter results met Wall Street’s revenue expectations, but the market responded negatively, reflecting investor concerns about profitability and future growth levers. Management attributed the quarter’s performance to robust organic growth in its Diagnostics segment—especially through increased demand for specialty and genetic testing platforms like Invitae. CEO Adam Schechter explained that \"margin for the quarter improved 100 basis points, driven by Diagnostics,\" and highlight",
    "url": "https://finnhub.io/api/news?id=af2f6aaf7f9e8cd326382eb1d6ae3bbb2840df052f69be5f922e46645ea3d4bd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762234584,
      "headline": "Labcorp’s Q3 Earnings Call: Our Top 5 Analyst Questions",
      "id": 137313068,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LH",
      "source": "Yahoo",
      "summary": "Labcorp’s third quarter results met Wall Street’s revenue expectations, but the market responded negatively, reflecting investor concerns about profitability and future growth levers. Management attributed the quarter’s performance to robust organic growth in its Diagnostics segment—especially through increased demand for specialty and genetic testing platforms like Invitae. CEO Adam Schechter explained that \"margin for the quarter improved 100 basis points, driven by Diagnostics,\" and highlight",
      "url": "https://finnhub.io/api/news?id=af2f6aaf7f9e8cd326382eb1d6ae3bbb2840df052f69be5f922e46645ea3d4bd"
    }
  }
]